108 related articles for article (PubMed ID: 12089783)
1. [Molecular pathologic diagnosis in solid tumors. What is clinically relevant?].
Werner M; Cabras AD; Höfler H
Pathologe; 2002 May; 23(3):170-3. PubMed ID: 12089783
[TBL] [Abstract][Full Text] [Related]
2. Amplification of ERBB-2 (HER-2/NEU) oncogene in different neoplasms of patients from USSR.
Knyazev PG; Imyanitov EN; Chernitca OI; Nikiforova IF; Hanson KP
Oncology; 1992; 49(2):162-5. PubMed ID: 1349430
[TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
4. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
Thor AD; Berry DA; Budman DR; Muss HB; Kute T; Henderson IC; Barcos M; Cirrincione C; Edgerton S; Allred C; Norton L; Liu ET
J Natl Cancer Inst; 1998 Sep; 90(18):1346-60. PubMed ID: 9747866
[TBL] [Abstract][Full Text] [Related]
5. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.
Wang S; Saboorian MH; Frenkel E; Hynan L; Gokaslan ST; Ashfaq R
J Clin Pathol; 2000 May; 53(5):374-81. PubMed ID: 10889820
[TBL] [Abstract][Full Text] [Related]
6. Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.
Wani G; Noyes I; Milo GE; D'Ambrosio SM
Mol Med; 1997 Apr; 3(4):273-83. PubMed ID: 9131589
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer.
Shpitz B; Bomstein Y; Sternberg A; Klein E; Liverant S; Groisman G; Bernheim J
J Surg Oncol; 2000 Dec; 75(4):252-7. PubMed ID: 11135266
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype.
Fiche M; Avet-Loiseau H; Heymann MF; Moussaly F; Digabel C; Joubert M; Classe JM; Dravet F; Fumoleau P; Ross J; Maugard CM
Int J Cancer; 1999 Oct; 84(5):511-5. PubMed ID: 10502729
[TBL] [Abstract][Full Text] [Related]
9. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
Moll UM; Riou G; Levine AJ
Proc Natl Acad Sci U S A; 1992 Aug; 89(15):7262-6. PubMed ID: 1353891
[TBL] [Abstract][Full Text] [Related]
10. Quantitative measurement of c-erbB-2 p185 and mutant p53 expression in ovarian neoplasms by enzyme immunoassay.
Mabrouk GM; Helal SA; El-Lamie KI; Khalifa A
Clin Chem; 1996 Jun; 42(6 Pt 1):981-2. PubMed ID: 8665697
[No Abstract] [Full Text] [Related]
11. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
Isola J; Visakorpi T; Holli K; Kallioniemi OP
J Natl Cancer Inst; 1992 Jul; 84(14):1109-14. PubMed ID: 1352359
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis of a metastatic breast tumor from ovarian cancer by the succession of a p53 mutation: a case report.
Mori R; Futamura M; Morimitsu K; Saigo C; Miyazaki T; Yoshida K
World J Surg Oncol; 2017 Jun; 15(1):117. PubMed ID: 28662703
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis markers in breast cancer--potentially useful tools for priority setting of anti-angiogenic agents.
Keyhani E; Muhammadnejad A; Behjati F; Sirati F; Khodadadi F; Karimlou M; Moghaddam FA; Pazhoomand R
Asian Pac J Cancer Prev; 2013; 14(12):7651-6. PubMed ID: 24460348
[TBL] [Abstract][Full Text] [Related]
14. [Overexpression of c-erbB-2 and p53 oncoprotein in renal pelvic and ureteral carcinomas with reference to the expression of Ki-67 antigen as a proliferation marker].
Hashimoto H; Sue Y; Tokumitsu M; Saga Y; Yachiku S
Nihon Hinyokika Gakkai Zasshi; 1997 Jun; 88(6):605-11. PubMed ID: 9234617
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma.
Kim R; Clarke MR; Melhem MF; Young MA; Vanbibber MM; Safatle-Ribeiro AV; Ribeiro U; Reynolds JC
Dig Dis Sci; 1997 Dec; 42(12):2453-62. PubMed ID: 9440619
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.
Sekido Y; Umemura S; Takekoshi S; Suzuki Y; Tokuda Y; Tajima T; Osamura RY
Int J Oncol; 2003 Jun; 22(6):1225-32. PubMed ID: 12738987
[TBL] [Abstract][Full Text] [Related]
18. Molecular markers in Paget disease of the breast.
Fu W; Lobocki CA; Silberberg BK; Chelladurai M; Young SC
J Surg Oncol; 2001 Jul; 77(3):171-8. PubMed ID: 11455553
[TBL] [Abstract][Full Text] [Related]
19. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation.
Kazakov DV; Ivan D; Kutzner H; Spagnolo DV; Grossmann P; Vanecek T; Sima R; Kacerovska D; Shelekhova KV; Denisjuk N; Hillen U; Kuroda N; Mukensnabl P; Danis D; Michal M
Am J Dermatopathol; 2009 May; 31(3):236-47. PubMed ID: 19384064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
